Empagliflozin improved clinical outcomes in patients with acute heart failure (AHF), regardless of blood pressure (BP) levels, with particularly strong benefits observed in those with diastolic BP ...

Empagliflozin, which in addition to treating type-2 diabetes, also aids weight loss, and reduces cardiovascular and kidney risks, holds significant promise for volume growth as it becomes more ...

The kind of, molecule, the API when we export is being ... will not be changed but new patients, would be given Empagliflozin. That’s a kind of an assumption we make. On the basis of that ...

Jardiance is also authorised to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. According to the FDA, heart disease impacts more than ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

We also published positive results from our LEGEND Phase 2 proof-of-concept study evaluating lanifibranor in combination with empagliflozin, which further elucidated the potential of lanifibranor ...

The diabetes care landscape in India is set for a major transformation as domestic pharmaceutical companies reportedly prepare to launch low-cost generic versions of Empagliflozin. The move comes ...

By introducing Empagliflozin at INR 5.49 per tablet for ... API raw material which is DMF grade,” he informed. The kind of, molecule, the API when we export is being used, the same has been ...